Eli Lilly (NYSE: LLY) has been an exceptional growth stock to own in recent years. Its popular GLP-1 treatments, Zepbound and Mounjaro, have been in high demand, and they are amassing billions in revenue for the business. Investors and analysts continue to expect much more growth from them in the future.
However, with Eli Lilly’s valuation at around $900 billion today, expectations are also sky-high. That can make it difficult for the stock to impress investors and generate strong returns in the future. Is Eli Lilly’s stock priced at too much of a premium to be a good buy right now, or is there still room for it to rise even higher?
Image source: Getty Images.
